Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIP-AML22: Complex open-label trial in newly diagnosed pediatric de novo AML
2022-002885-34Phase 3Active
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of etoposide, methotrexate and cytarabine in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Event Free Survival. Started Jan 2023; status: active.
02
Drugs
etoposidemethotrexatecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-002885-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002885-34.